CXCL8 and palmoplantar pustulosis: New molecules under development for PPP include an anti-IL-8 monoclonal antibody (HuMab 10F8) that in an open-label trial has demonstrated a decrease of 50% or more in new pustule formation at week 8 in 67% of PPP patients43.